HCA (HCA) CEO Samuel Hazen logs multi-block share sales and trust transfer
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
HCA Healthcare (HCA) CEO and director Samuel N. Hazen reported multiple open‑market sales of HCA common stock on February 3, 2026, at weighted average prices ranging from about $497.18 to $502.95 per share. After these sales, he directly held 32,276 shares of HCA common stock.
On February 4, 2026, Hazen reported a transfer of 1,045 shares at $498.35 per share to a trust under a power of substitution, in exchange for assets of equal value. The footnote states this was a change in the form of beneficial ownership and did not change the total number of HCA shares he may be deemed to beneficially own. Following the transfer, he directly held 31,231 shares and had additional indirect holdings through various trusts and a limited partnership, including 16,024 shares held by HD Trust and 813,320 shares held by an LP.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 42,877 shares ($21,483,275)
Net Sell
14 txns
Insider
HAZEN SAMUEL N
Role
CEO
Sold
42,877 shs ($21.48M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock | 1,045 | $498.35 | $521K |
| Other | Common Stock | 1,045 | $498.35 | $521K |
| Sale | Common Stock | 14,716 | $502.9482 | $7.40M |
| Sale | Common Stock | 5,002 | $502.1505 | $2.51M |
| Sale | Common Stock | 7,395 | $500.6932 | $3.70M |
| Sale | Common Stock | 6,189 | $500.0176 | $3.09M |
| Sale | Common Stock | 5,162 | $498.7977 | $2.57M |
| Sale | Common Stock | 4,293 | $498.123 | $2.14M |
| Sale | Common Stock | 120 | $497.1783 | $60K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 31,231 shares (Direct);
Common Stock — 16,024 shares (Indirect, By HD Trust)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.49 to $503.485, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.485 to $502.455, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.44 to $501.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $499.47 to $500.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.41 to $499.395, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.49 to $498.385, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.10 to $497.38, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Pursuant to a power of substitution, on February 4, 2026, the Reporting Person transferred 1,045 shares of common stock of the Issuer to a trust in exchange for assets of equal value. The transfer was made at a price per share equal to $498.35 (the average of the high and low prices of shares of common stock of the Issuer on February 4, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the Reporting Person may be deemed to have beneficial ownership. The Reporting Person believes that the transfer of shares to the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934.
FAQ
What insider activity did HCA (HCA) report for CEO Samuel Hazen?
HCA reported that CEO Samuel N. Hazen sold HCA common stock in multiple open‑market transactions on February 3, 2026, and then transferred 1,045 shares to a trust on February 4, 2026, as a change in the form of beneficial ownership.
What do the weighted average prices in Samuel Hazen’s HCA trades mean?
Each reported transaction price is a weighted average of multiple trades executed within a specified price range. The footnotes explain that individual trades occurred at different prices within each range, and Hazen will provide exact trade‑level details upon request to shareholders or regulators.